Abstract
Diabetic micro- and macroangiopathies are leading causes of acquired blindness, end-stage renal failure and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for vascular complications in diabetes. However, the strict control of blood glucose or BP is often difficult to maintain, and current therapeutic options are far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target vascular complications in diabetes may be actually desired for most patients with diabetes. Pigment epithelium- derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes. This article summarizes the pathophysiological role of PEDF for vascular complication in diabetes and its potential therapeutic implication in this devastating disorder.
Keywords: Diabetic vascular complications, AGEs, oxidative stress, PEDF, RAGE
Current Drug Targets
Title: Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications
Volume: 9 Issue: 11
Author(s): Sho-ichi Yamagishi, Takanori Matsui, Kazuo Nakamura, So Ueda, Yoshihiro Noda and Tsutomu Imaizumi
Affiliation:
Keywords: Diabetic vascular complications, AGEs, oxidative stress, PEDF, RAGE
Abstract: Diabetic micro- and macroangiopathies are leading causes of acquired blindness, end-stage renal failure and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for vascular complications in diabetes. However, the strict control of blood glucose or BP is often difficult to maintain, and current therapeutic options are far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target vascular complications in diabetes may be actually desired for most patients with diabetes. Pigment epithelium- derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes. This article summarizes the pathophysiological role of PEDF for vascular complication in diabetes and its potential therapeutic implication in this devastating disorder.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Matsui Takanori, Nakamura Kazuo, Ueda So, Noda Yoshihiro and Imaizumi Tsutomu, Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications, Current Drug Targets 2008; 9 (11) . https://dx.doi.org/10.2174/138945008786786154
DOI https://dx.doi.org/10.2174/138945008786786154 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Current Diabetes Reviews Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction
Current Diabetes Reviews Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Current Medicinal Chemistry Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) Vitamin D Replacement and Type 2 Diabetes Mellitus
Current Diabetes Reviews Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying Hypothesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Current Pharmaceutical Design Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Urate Transport: Regulators of Serum Urate Levels in Humans
Current Rheumatology Reviews Diabetes Beyond Insulin: Review of New Drugs for Treatment of Diabetes Mellitus
Current Drug Discovery Technologies Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design Transfection of TGF-β shRNA by Using Ultrasound-targeted Microbubble Destruction to Inhibit the Early Adhesion Repair of Rats Wounded Achilles Tendon In vitro and In vivo
Current Gene Therapy Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine